What the business is, and whether it's a good one at a fair price.
Manufactures active pharmaceutical ingredients (APIs) and medical devices, with a growing contract development and manufacturing (CDMO) arm. The API business sells intermediates and active ingredients for molecules such as loratadine, desloratadine, montelukast, atorvastatin, rosuvastatin and fexofenadine to formulation customers worldwide, with export share at 72.1% of revenue in FY25. The medical devices business sells glucometers, blood pressure monitors and test strips through a B2C push, with a 14.2 million-unit glucometer installed base and 41 crore strips sold. A Rs 825 crore CDMO mandate from a global multinational moved into commercial execution in Q1 FY27, with capacity targeted to scale toward 1,000 KL in phases. API production capacity is being expanded from 314 KL to 600 KL by FY26, and the medical representative force is being scaled from 200 to 1,200 over three years to support an India formulations push. The cost base is dominated by materials at 57.8% of revenue, with employees at 12.9% and other operating expenses at 17.9%.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from MOREPEN LAB. LTD's filed financials and exchange disclosures
MOREPEN LAB. LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol MOREPENLAB.
Yes. Over the trailing twelve months MOREPEN LAB. LTD reported a net profit of ₹141 Cr on revenue of ₹1,951 Cr.
Yes. The dividend yield is 0.17% at the current price. It paid out 11% of its profit as dividend in FY26.
No. Debt stands at 0.16× equity, and it carries net debt of ₹164 Cr. That is lower than 48% of its 171 Pharmaceuticals peers.
On trailing P/E, MOREPEN LAB. LTD ranks 124 of 169 in Pharmaceuticals — cheaper than 27% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session MOREPEN LAB. LTD moves 1.53% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by MOREPEN LAB. LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
